In the first part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains how ...
In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant ...
Often referred to as AFPs, alternative funding programs are a third-party entity that works hand-in-hand with self-funded health plans to determine other ways to cover plan participants’ specialty ...
For the first time, CMS has released negotiated prices for high-cost drugs covered under both Medicare Part D and Part B, ...
Lastly, Insilico Medicine has inked a $120 million deal with Qilu Pharmaceuticals. The company will be using Insilico’s ...
More than a decade after the Drug Quality and Security Act (DQSA) of 2013 created the 503B category, the central question ...
Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to ...
In the final part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, explains how federated ...
Morris & Dickson's acquisition of Prodigy Health strengthens its specialty pharmaceutical distribution and expands access to ...
The US-EU standoff over Greenland has threatened pharmaceutical supply chains, risking increased costs and delays in drug development and patient access. European leaders have prepared to counter US ...
In the second part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, describes how AI-driven ...
In today’s Pharma Pulse, extreme weather tests the resilience of community pharmacies, while CMS proposes a near-flat 0.09% update for Medicare Advantage and Part D payments in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results